Kura Oncology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kura Oncology, Inc. on February 4, 2016, covering events that occurred on January 29, 2016. The filing details executive compensation adjustments and the establishment of corporate performance goals for the 2016 fiscal year.
Key Financial Metrics and Compensation
The filing does not provide consolidated financial statements, revenue, profit, cash flow, or debt metrics. It focuses exclusively on executive compensation actions approved by the Board of Directors:
- CEO (Troy Wilson): Received a $195,000 annual performance cash bonus (100% achievement of goals). Granted an option to purchase 125,000 shares at $4.80 per share. Base salary increased from $390,000 to $429,000.
- CFO (Heidi Henson): Received a $105,000 annual performance cash bonus (75% corporate goals, 25% individual performance). Granted an option to purchase 80,000 shares at $4.80 per share. Base salary increased from $300,000 to $313,900.
- Stock Price: The exercise price for new options was set at $4.80, reflecting the closing price on January 29, 2016.
Material Changes and Contract Amendments
The Board approved an amendment to Dr. Wilson's executive employment agreement regarding change-of-control provisions. The cash lump-sum payment entitlement upon termination without cause or resignation with good reason in connection with a change of control was increased from 12 months to 15 months of the executive's then annual base salary.
Guidance, Outlook, and Corporate Goals
The Board approved target bonus percentages and corporate goals for 2016:
- Target Bonus Percentages: CEO at 50% of base salary; CFO at 35% of base salary.
- Goal Structure: Goals include performance objectives for advancing pre-clinical and clinical programs, as well as financial goals.
- Additional Development Goals: Weighted up to 50% towards overall corporate goal achievement, these are only eligible if 85% of base corporate goals are achieved.
Investor Verification Checklist
- Verify the total number of shares outstanding and the dilution impact of the 205,000 new options granted to the CEO and CFO.
- Review the specific "financial goals" and "clinical program objectives" defined for 2016 to assess the difficulty of achieving the target bonuses.
- Confirm the terms of the employment agreement amendment regarding the 15-month change-of-control payment in future filings.
- Monitor the company's cash position to ensure it can sustain the increased annual salary obligations and potential bonus payouts.